Baker McKenzie acted as lead legal counsel to Aztiq ("Aztiq") in its acquisition of a 100% stake in Alvogen Emerging Markets Holdings Limited ("AEMH"), via a consortium formed with co-investor Innobic (Asia) Company Limited ("Innobic") from its existing shareholders for USD475 million. This transaction, among the largest in the healthcare industry this year, will result in the Aztiq-Innobic consortium becoming the lead shareholder in the global oncology pharmaceutical company Lotus Pharmaceuticals ("Lotus", TWSE ticker: 1795) and the sole shareholder of Alvogen Malta Holding Ltd., the owner of Adalvo, a global business-to-business pharmaceutical company. 

A multi-jurisdictional, multi-practice team of transactional and advisory specialists had worked on this transaction, led by Singapore-based M&A partner Kay Moon. The other lawyers who were involved in this transaction include, among others, Robert Wright, Timon Chiong, Joanne Chong, Liang Jun Ong and Charlie Wong from the M&A team across Singapore and Hong Kong; and Stephen Crosswell, Tom Jenkins, Lip Hang Poh and Vivian Tsang from the antitrust/merger control team in Hong Kong and Singapore; and Alex Chiang and Hao-Ray Hu from the capital markets/finance team in Taipei. 

"We are very proud to have been part of this strategic investment with our client Aztiq, whose ambitions to grow its research innovation capabilities and business reach by partnering with Innobic on this deal, also reflects the momentum in the healthcare and pharmaceutical sector that we have seen for the past 18 months now," said Kay.  

The alliance between Aztiq and Innobic, and with the completion of the AEMH deal, will create a global pharmaceuticals enterprise with extensive resources, networks and reach all over the world. AEMH is currently owned by Alvogen Lux Holdings Sarl (“Alvogen Lux”). Key shareholders in Alvogen Lux include CVC Capital Partners and Temasek Holdings of Singapore, as well as Aztiq. Alvogen Lux will remain a leading shareholder in the generic pharmaceuticals company Alvogen US, including specialty pharma company Almatica, as well as the second largest shareholder in global biosimilars company Alvotech.
Explore Our Newsroom